Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adcetris and ACVD in Advanced Hodgkin Lymphoma (Optimist)
NCT03527628Phase 2Unknown
- Sponsor
- King Abdullah International Medical Research Center
- Start
- Jan 2018
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL), sponsored by King Abdullah International Medical Research Center. Status: unknown.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT03527628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03527628.